Glibenclamide site of in insuline: A new chance for MODY 3 type diabetes patients: Case report;Glibenklamid místo inzulinu: Nová šance pro pacienty s diabetem MODY 3: Kazuistika

Vnitrni Lekarstvi

Volumn 52, Issue 3, 2006, Pages 275-279

  Brunerová, Ludmila ^a   Treslova L ^a   Pruhova S ^a   Vosahlo J ^a   Broz J ^a   Lebl, J ^a   Andel M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Glibenclamide; Metabolic control; MODY 3 type diabetes; Quality of life; Therapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARGININE; C PEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; GLYCINE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INSULIN; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR 1; TOLBUTAMIDE; TRIACYLGLYCEROL;

CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE MUTATION; HUMAN; HYPOGLYCEMIA; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MATURITY ONSET DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW;

ADOLESCENT; AGE OF ONSET; DIABETES MELLITUS, TYPE 2; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MUTATION; PEDIGREE; QUALITY OF LIFE;

EID: 33645974053     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Yamagata K, Oda N, Kausami PJ et al. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the zouny (MODY 3). Nature 1996; 384: 455-458.
2. Brunerová L, Brož J, Průhová Š et al. Maturity-onset diabetes of the young 3. DMEV 2006; (rukopis).
3. Timsit J, Bellanné-Chantelot Ch, Dubois-Laforgue D et al. Diagnosis and management of Maturity-Onset Diabetes of the Young. Treat Endocrinol 2005; 4: 9-18.
4. Mitchell S, Frayling T. The role of transcription factors in maturity-onset diabetes of the young. Mol Genet Metab 2002; 77: 35-43.
5. Kim SH, Ma X, Klupa T et al. Genetic modifiers of the age at diagnosis of diabetes (MODY 3) in carriers of HNF-1α mutations map to chromosomes 5p15, 9q22 and 14q24. Diabetes 2003; 52: 2182-2186.
6. Lehto M, Tupni T, Mahtani MM et al. Characterization of the MODY 3 phenotype: early onset diabetes caused by an insulin secretion defect. J Clin Invest 1997; 99: 582-591.
7. Klimeš I, Gašperíková D, Michálek J. DNA diagnostika monogennych foriem diabetu na Slovensku: január 2005. DMEV 2005; 8: 27.
8. Owen KR, Shepherd M, Stride A et al. Heterogenity in young adult onset diabetes - aetiology alters clinical characteristics. Diabet Med 2002; 19: 758-761.
9. Owen KR, Stride A, Ellard S et al. Etiological investigation in young adults presenting with apparent type 2 diabetes. Diabetes Care 2003; 26: 2088-2093.
10. Moller AM, Dalgaard LT, Pociot F et al. Mutations in the hepatocyte nuclear factor 1-α gene in Caucasian families originally classified as having type 1 diabetes. Diabetologia 1998; 41: 1528-1531.
11. Isomaa B, Henricsson M, Lehto M et al. Chronic diabetic complications in patients with MODY 3 diabetes. Diabetologia 1998; 41: 467-473.
12. Hattersley AT. Maturity onset diabetes of the young: clinical heterogenity explained by genetic heterogenity. Diabet Med 1998; 15: 15-24.
13. Shepherd M, Hattersley A. I don't feel like a diabetic any more: the impact of stopping insulin in patients with maturity-onset diabetes of the young following genetic testing. Clin Med 2004; 4: 144-147.
14. Pearson E, Starkey B, Powell R et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362: 1275-1281.
15. Shepherd M, Pearson E, Houghton J et al. No deterioration in glycaemic control in HNF-1α Maturity-Onset Diabetes of the Young following transfer from long-term insulin to sulphonylureas. Diab Care 2003; 26: 3191-3192.
16. www.dawnstudy.com
17. Vaxillaire M, Pueyo ME, Clément K et al. Insulin secretion and insulin sensitivity in diabetic and non-diabetic subjects with HNF-1α mutations. Eur J Endocrinol 1999; 141: 609-618.
18. Pearson E, Liddell W, Shepherd M et al. Sensitivity to sulphonylureas in patients with HNF-1α gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000; 17: 543-545.
19. Boileau P, Wolfrum Ch, Shih D et al. Decreased glibenclamide uptake in hepatocytes of HNF-1α defficient mice. Diabetes 2002; 51: S343-S348.
20. Sagen JV, Pearson ER, Johansen A et al. Preserved insulin response to tolbutamide in HNF-1alpha mutation carriers. Diabet Med 2005; 22: 406-409.
21. Yamagata K, Nammo T, Moriwaki M et al. Overexpression of dominant-negative mutant HNF-1α in pancreatic β-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced β-cell proliferation and diabetes. Diabetes 2002; 51: 114-123.
22. Richter S, Shih D, Pearson E et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003; 52: 2989-2995.
23. Dunne M, Cosgrove K, Shepherd M et al. Potassium channels, sulphonylurea receptors and control of insulin release. Trends Endocrinol Metab 1999; 10: 146-152.